Skip to main content
. Author manuscript; available in PMC: 2009 Jun 11.
Published in final edited form as: Oncogene. 2008 Sep 22;27(58):7274–7284. doi: 10.1038/onc.2008.333

Figure 5. EZH2 regulates E-cadherin promoter activity.

Figure 5

(a) Benign breast cell lines H16N2, MCF10A and HME were transfected with an E-cadherin-luciferase promoter construct and infected with either EZH2, EZH2ΔSET or control adenovirus. EZH2 infected cells were also incubated with 500nM SAHA. Relative luciferase activity (RLA) was assessed. (b) Knockdown of EZH2 in DU145 cells induces E-cadherin promoter activity. EZH2 expression was inhibited by RNA interference in DU145 cells that were transfected with the E-cadherin promoter-luciferase construct. The p value was calculated between EZH2 RNAi and scrambled RNAi samples. (c) Ectopically expressed EZH2 functions in a complex with endogenous PRC2 components SUZ12 and EED. H16N2 cells were infected with myc-tagged EZH2 and control adenovirus as well as EZH2 infected cells treated with 500nM SAHA for 48 hours. Immunoprecipitation was carried out using anti-myc antibody, and subsequent Western blotting performed with either SUZ12 or EED antibody.